GlassScriptPhysician profile
Sepehr Rokhsar
NPI 1437182805
$150,312.22
in general payments reported to CMS, 2019-2025
10 companies · $36K in 2025
The $36K reported for 2025 was more than what 95% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,130 · 2020: $3,336 · 2021: $12K · 2022: $21K · 2023: $50K · 2024: $25K · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $85K · Travel and Lodging: $15K · Consulting Fee: $8,638 · Food and Beverage: $3,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $85,106.47 |
| Travel and Lodging | $15,239.01 |
| Consulting Fee | $8,638.00 |
| Food and Beverage | $3,137.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $98,359.81 | 2020-2025 | Jakafi, Jakafi |
| Seagen INC. | $34,140.52 | 2023 | Adcetris |
| Pfizer INC. | $9,726.34 | 2020-2025 | |
| Kite Pharma, INC. | $6,307.42 | 2022 | |
| Janssen Biotech, INC. | $1,293.04 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $200.00 | 2022 | |
| Beone Medicines USA, INC. | $106.29 | 2025 | Brukinsa |
| Abbvie INC. | $92.00 | 2023 | Venclexta |
| E.R. Squibb & Sons, L.L.C. | $60.84 | 2019-2020 | |
| Tempus Ai, INC | $25.96 | 2025 | Xt Cdx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sepehr Rokhsar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.